Omega-backed startup sells itself quietly; AbbVie breaks out more Rinvoq data; Revance gets FDA date for Botox rival
→ When it came into the limelight with a $35 million Series A financing in 2018, Attenua promised to repurpose three oral neuronal nicotinic receptor assets discarded by Catalyst Biosciences (which in turn got the drugs through a merger with Targacept). But now that it’s wrapped a proof-of-concept trial of the lead drug in chronic cough, Attenua is flipping the portfolio to another buyer for yet another use.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.